Phase I/II study of capmatinib plus erlotinib in patients with MET-positive non–small-cell lung cancer
CE McCoach, A Yu, DR Gandara, JW Riess… - JCO precision …, 2021 - ascopubs.org
… resistant to erlotinib, and cohort B enrolled erlotinib-naïve … In this study, we demonstrated
that standard-dose erlotinib … A study in Chinese patients with gefitinib plus capmatinib also …
that standard-dose erlotinib … A study in Chinese patients with gefitinib plus capmatinib also …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
… A Markov model was designed to simulate outcomes of a hypothetical cohort of advanced
(… -guided use of a TKI (afatinib, erlotinib, and gefitinib). Model outcome measures were direct …
(… -guided use of a TKI (afatinib, erlotinib, and gefitinib). Model outcome measures were direct …
Association of EGFR tyrosine kinase inhibitor treatment with progression-free survival among Taiwanese patients with advanced lung adenocarcinoma and EGFR …
PY Chen, CC Wang, CN Hsu, CY Chen - Frontiers in Pharmacology, 2021 - frontiersin.org
… study aimed to compare the relative survival rate of gefitinib, … The retrospective
population-based cohort study was … 20% in our cohort, and results exhibited that both erlotinib and …
population-based cohort study was … 20% in our cohort, and results exhibited that both erlotinib and …
68P Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
W Liang, Q He, C Li, H Liang, B Cheng, J He - Journal of Thoracic Oncology, 2021 - jto.org
… Conclusions: Within our cohort of patients, approximately a quarter of our patients received
adjuvant chemotherapy, relatively similar to what was observed in the ADAURA study. The …
adjuvant chemotherapy, relatively similar to what was observed in the ADAURA study. The …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
… a retrospective cohort study using data from the claims database of Taipei Veterans General
Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and …
Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and …
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
… The results of the study show that afatinib therapy was superior to erlotinib and gefitinib as
first-… type used was an analytic observational retrospective cohort study. The subjects of the …
first-… type used was an analytic observational retrospective cohort study. The subjects of the …
Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: a …
L Xing, G Wu, L Wang, J Li, J Wang, Z Yuan… - International Journal of …, 2021 - Elsevier
… Preclinical studies demonstrated that EGFR TKIs, such as gefitinib and erlotinib, disrupted …
Our trial provided valuable EGFR-mutation profiling data in a relatively large cohort of patients …
Our trial provided valuable EGFR-mutation profiling data in a relatively large cohort of patients …
Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study
V Alanen, S Iivanainen, M Arffman, JP Koivunen - Acta Oncologica, 2021 - Taylor & Francis
… TKIs (gefitinib, erlotinib, … gefitinib and afatinib is based on the advanced disease and the
presence of activating tumor EGFR mutations. On the other hand, the reimbursement for erlotinib …
presence of activating tumor EGFR mutations. On the other hand, the reimbursement for erlotinib …
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase …
C Xie, Z Jing, H Luo, W Jiang, L Ma, W Hu… - British Journal of …, 2020 - nature.com
… II studies reported the promising efficacy of concurrent radiotherapy with gefitinib or erlotinib
… in EGFR IHC-positive patients because the EGFR IHC cohort represents a poorer outcome …
… in EGFR IHC-positive patients because the EGFR IHC cohort represents a poorer outcome …
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
… relative to first-generation gefitinib/erlotinib, and a broad … gefitinib in the front-line
treatment of EGFR-mutated NSCLC. … real-world studies involving first-generation gefitinib/erlotinib …
treatment of EGFR-mutated NSCLC. … real-world studies involving first-generation gefitinib/erlotinib …